Publications

Abstract Insulin is the major endocrine hormone responsible for regulating whole-body glucose homeostasis by regulating glucose uptake in insulin-sensitive tissue. Obesity is one of the main factors initiating the development of insulin resistance through increased adipose tissue size, inflammation, and ectopic fat deposition in insulin-sensitive tissues. Inflammation and fat accumulation are key drivers for losing […]

Abstract Insulin is the major endocrine hormone responsible for regulating whole-body glucose homeostasis by regulating glucose uptake in insulin-sensitive tissue. Obesity is one of the main factors initiating the development of insulin resistance through increased adipose tissue size, inflammation, and ectopic fat deposition in insulin-sensitive tissues. Inflammation and fat accumulation are key drivers for losing […]

Abstract Insulin is the major endocrine hormone responsible for regulating whole-body glucose homeostasis by regulating glucose uptake in insulin-sensitive tissue. Obesity is one of the main factors initiating the development of insulin resistance through increased adipose tissue size, inflammation, and ectopic fat deposition in insulin-sensitive tissues. Inflammation and fat accumulation are key drivers for losing […]

Abstract Insulin is the major endocrine hormone responsible for regulating whole-body glucose homeostasis by regulating glucose uptake in insulin-sensitive tissue. Obesity is one of the main factors initiating the development of insulin resistance through increased adipose tissue size, inflammation, and ectopic fat deposition in insulin-sensitive tissues. Inflammation and fat accumulation are key drivers for losing […]

Abstract Insulin is the major endocrine hormone responsible for regulating whole-body glucose homeostasis by regulating glucose uptake in insulin-sensitive tissue. Obesity is one of the main factors initiating the development of insulin resistance through increased adipose tissue size, inflammation, and ectopic fat deposition in insulin-sensitive tissues. Inflammation and fat accumulation are key drivers for losing […]

Abstract Long-acting dual amylin and calcitonin receptor agonists (DACRAs) are novel candidates for the treatment of type 2 diabetes and obesity due to their beneficial effects on body weight, glucose control, and insulin action. However, how the metabolic benefits are maintained after long-lasting treatment is unknown. This study investigates the long-term anti-obesity and anti-diabetic treatment […]

Abstract BACKGROUND Despite the extensive research to provide a disease-modifying osteoarthritis drug (DMOAD), there is still no approved DMOAD. Dual amylin and calcitonin receptor agonists (DACRA) can provide metabolic benefits along with antinociceptive and potential structural preserving effects. In these studies, we tested a DACRA named KBP-336 on a metabolic model of OA in meniscectomised […]

Abstract BACKGROUND AND PURPOSE Insulin therapies for Type 1 diabetes (T1D) have limitations, such as glucose fluctuations, hypoglycaemia, and weight gain. Only pramlintide is approved with insulin. However, its short half-life limits efficacy, requiring multiple daily injections and increasing hypoglycaemia risk. New strategies are needed to improve glycaemic control. Dual amylin and calcitonin receptor agonists […]

Abstract Dual amylin and calcitonin receptor agonists (DACRAs) are effective treatments for obesity and type 2 diabetes (T2D). They provide beneficial effects on body weight, glucose control, and insulin action. However, whether DACRAs protect against diabetes-related kidney damage remains unknown. We characterize the potential of long-acting DACRAs (KBP-A, Key Bioscience Peptide-A) as a treatment for […]

Abstract OBJECTIVE Long-acting dual amylin and calcitonin receptor agonists (DACRAs) hold great promise as potential treatments for obesity and its associated comorbidities. These agents have demonstrated beneficial effects on body weight, glucose control, and insulin action mirroring the effects observed with glucagon-like peptide-1 (GLP-1) agonist treatment. Strategies aimed at enhancing and prolonging treatment efficacy include […]